Genmab (GMAB) has released an update.
Genmab A/S, a medical research and pharmaceutical company headquartered in Copenhagen, has updated its Articles of Association. The company has authorized the Board of Directors to issue new shares and warrants, and increase the share capital with or without pre-emption rights for existing shareholders, up to a total nominal value of DKK 6,600,000 by March 2029. These financial instruments are intended to be negotiable and registered in the names of their holders.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
